542 related articles for article (PubMed ID: 27696222)
21. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
22. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
23. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D
Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661
[TBL] [Abstract][Full Text] [Related]
24. RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.
Wang H; Wang X; Xu L; Zhang J
World Neurosurg; 2023 Aug; 176():e610-e622. PubMed ID: 37271257
[TBL] [Abstract][Full Text] [Related]
25. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
26. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
27. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
[TBL] [Abstract][Full Text] [Related]
28. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
29. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
[TBL] [Abstract][Full Text] [Related]
30. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
32. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
[TBL] [Abstract][Full Text] [Related]
33. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
Laffaire J; Everhard S; Idbaih A; Crinière E; Marie Y; de Reyniès A; Schiappa R; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Thillet J; Ducray F
Neuro Oncol; 2011 Jan; 13(1):84-98. PubMed ID: 20926426
[TBL] [Abstract][Full Text] [Related]
34. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
[TBL] [Abstract][Full Text] [Related]
35. IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.
Zhang XQ; Kiang KM; Wang YC; Pu JK; Ho A; Cheng SY; Lee D; Zhang PD; Chen JJ; Lui WM; Fung CF; Leung GK
J Neurooncol; 2015 Nov; 125(2):253-63. PubMed ID: 26337623
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value and their clinical implication of 89-gene signature in glioma.
Shahid M; Cho KM; Nguyen MN; Choi TG; Jo YH; Aryal SN; Yoo JY; Yun HR; Lee JW; Eun YG; Lee JS; Kang I; Ha J; Yoon HJ; Kim SY; Kim SS
Oncotarget; 2016 Aug; 7(32):51237-51250. PubMed ID: 27323413
[TBL] [Abstract][Full Text] [Related]
37. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 5-Signature Predicting Survival of Patients with Lower-Grade Glioma.
Xiao H; Bai J; Yan M; Ji K; Tian W; Liu D; Ning T; Liu X; Zou J
World Neurosurg; 2019 Jun; 126():e765-e772. PubMed ID: 30853516
[TBL] [Abstract][Full Text] [Related]
39. A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
Dahlrot RH; Kristensen BW; Hjelmborg J; Herrstedt J; Hansen S
J Neurooncol; 2013 Sep; 114(3):309-17. PubMed ID: 23817809
[TBL] [Abstract][Full Text] [Related]
40. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
